Sign in
Back
Rituximab administration guidelines for the haematology patient: a critical literature review
Journal article   Peer reviewed

Rituximab administration guidelines for the haematology patient: a critical literature review

Christine Bristow, Kirstine Shrubsole and Nedeljka Rosic
Australian Journal of Cancer Nursing, Vol.22(1), pp.2-8
31/05/2021
DOI: https://doi.org/10.33235/ajcn.22.1.2-8
url
Rituximab administration guidelines for the haematology patientView
Published (Version of record)

Metrics

34 Record Views

Abstract

Rituximab Lymphoma Leukaemia Hypersensitivity reaction Administration Clinical Nursing: Secondary (Acute Care) Clinical Pharmacology and Therapeutics Cancer and Related Disorders
Rituximab is a chimeric monoclonal antibody that targets the cluster of differentiation-20 cells found in patients with B-cell leukaemia or lymphoma. Rituximab is administered in conjunction with complex chemotherapy regimens to enhance probability of longer remission. However, rituximab can cause a hypersensitivity reaction due to the large cytokine release. Therefore, rituximab is administered very slowly on the first exposure.

Details